DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Australia
  • /
  • Healthcare
Author Program NEWCreate Narrative
PME logo

Pro Medicus Limited Stock Price

ASX:PME Community·AU$17.4b Market Cap
  • 6 Narratives written by author
  • 8 Comments on narratives written by author
  • 226 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

PME Share Price Performance

AU$0
-297.08 (-100.00%)
​
AU$196.78
Fair Value
AU$0
-297.08 (-100.00%)
​
Price AU$0
Tue, 10 Mar 26
Fair ValueAU$196.78
Share Pricen/a

PME Community Narratives

ZA
ZayaanS's
Fair Value
·
Fair Value AU$196.78 15.2% undervalued intrinsic discount

Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business

22users have liked this narrative
8users have commented on this narrative
46users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value AU$202.47 17.6% undervalued intrinsic discount

Cloud Imaging And AI Adoption Will Drive Long Term Healthcare Platform Dominance

0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value AU$108.55 53.7% overvalued intrinsic discount

Cloud Imaging And AI Risks Will Persist Yet Support Long Term Upside Potential

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
PME logo
Pro Medicus
15.2% undervalued intrinsic discount

Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business

View narrative
ZA
ZayaanS
Published 1 Mar
Read Narrative
PME logo
Pro Medicus
16.4% undervalued intrinsic discount

A stock I’m bullish on is Pro Medicus Limited (ASX: PME), an Australian healthcare technology company that develops medical imaging software

View narrative
KS
ks3
Published 8 Mar
Read Narrative
PME logo
Pro Medicus
24.8% overvalued intrinsic discount

Great Company.... but so expensive!

View narrative
RO
Robbo
Emerging Author
Robbo
Published 6 Jul 2025
Read Narrative
PME logo
Pro Medicus
17.6% undervalued intrinsic discount
Updated

Cloud Imaging And AI Adoption Will Drive Long Term Healthcare Platform Dominance

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 4 Sep
Read Narrative
PME logo
Pro Medicus
53.7% overvalued intrinsic discount

Cloud Imaging And AI Risks Will Persist Yet Support Long Term Upside Potential

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 21 Aug
Read Narrative
PME logo
Pro Medicus
33.3% undervalued intrinsic discount

Cloud Imaging And AI Integration Will Reshape Long Term Earnings Power

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 24 Jul
Read Narrative

Trending Discussion

JO
PME logo

which KLAS category is Pro Medicus winning? Sectra won 7 categories last time

0
|
0

Recently Updated Narratives

KS
PME logo

A stock I’m bullish on is Pro Medicus Limited (ASX: PME), an Australian healthcare technology company that develops medical imaging software

Fair Value: AU$199.7 16.4% undervalued intrinsic discount
11 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
ZA
PME logo

Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business

Fair Value: AU$196.78 15.2% undervalued intrinsic discount
46 fair values setusers have set this as their fair value
8 commentsusers have commented on this narrative
0 likesusers have liked this narrative
RO
Robbo
PME logo

Great Company.... but so expensive!

Fair Value: AU$133.68 24.8% overvalued intrinsic discount
22 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with solid track record.

1 Risk
2 Rewards
View Full Analysis

Pro Medicus Limited Key Details

AU$261.7m

Revenue

AU$401.0k

Cost of Revenue

AU$261.3m

Gross Profit

-AU$4.1m

Other Expenses

AU$265.3m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
2.54
99.85%
101.40%
0%
View Full Analysis

About PME

Founded
1983
Employees
153
CEO
Sam Hupert
WebsiteView website
www.promed.com.au

Pro Medicus Limited, a healthcare informatics company, provides medical imaging software and services to hospitals, imaging centers, and health care groups in Australia, Europe, and North America. The company offers Visage RIS, an enterprise-class radiology information system for patient registration, billing, scheduling, typing, HL7 integration, financial reporting, picture archive and communication system (PACS) integration, digital dictation, and voice recognition integration; and Visage RIS/PACS, a solution for imaging needs of organizations. It also provides Visage 7 Enterprise Imaging Platform, a healthcare imaging software for radiologists, physicians, and clinicians for access and visualization capability comprising rapidly viewing 2-D, 3-D, and 4-D medical images, as well as PACS, digital imaging software, training, installation, and professional services and support products; and Visage Ease, a native mobile application for access to medical imaging results stored on a Visage 7 server from iOS devices, including iPad, iPhone, and iTouch. In addition, the company offers Visage Ease Pro for interpreting diagnostic imaging studies; and Promedicus.net, an e-health offering. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.

Recent PME News & Updates

User avatar
Narrative Update • Sep 04

PME: Rising FY26 Cash Returns Will Support Optimistic US Market Share Hopes

Analysts have lifted their price target for Pro Medicus to A$202.47 from A$190.74, reflecting updated assumptions for slightly higher revenue growth and a lower future P/E. They also note that current market pricing already appears to bake in very optimistic long term US PACS market share gains.
User avatar
Narrative Update • Aug 21

PME: US Market Share Assumptions Will Likely Trigger Future Share Price Reset

Analysts have lifted their price target for Pro Medicus to A$192.60, up from A$147, while flagging that current market pricing already reflects a very large assumed gain in US PACS market share by FY35E. What’s in the News for Pro Medicus Pro Medicus signed a 7 year A$23 million contract with St. Luke's Health System in the United States to deploy its cloud based Visage 7 Enterprise Imaging Platform across three states, including Boise, Idaho.

Recent updates

No updates

Pro Medicus Limited Competitors

SIG logo

Sigma Healthcare

Symbol: ASX:SIG
Market cap: AU$30.7b
RHC logo

Ramsay Health Care

Symbol: ASX:RHC
Market cap: AU$12.3b
SHL logo

Sonic Healthcare

Symbol: ASX:SHL
Market cap: AU$9.6b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide